Company intelligence / Profile preview
Gliknik
Baltimore, Maryland, United Statesgliknik.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Phase 1
01
Overview
GL-2045 has completed numerous intravenous cohorts and five subcutaneous cohorts in healthy participants and is advancing to CIDP patients. GL-0719 is currently in Phase 1 clinical trials assessing safety, tolerability, drug levels, and complement inhibition.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Recombinant Fc fusion proteinsBiologics
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Pfizer (investor)
Beyond the preview
Go deeper on Gliknik.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gliknik.